Omega-3-acid ethyl esters (Lovaza) for severe hypertriglyceridemia

P and T

Volumn 33, Issue 5, 2008, Pages

  Koski, Renee R ^a  

^a FERRIS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ATORVASTATIN; C REACTIVE PROTEIN; DOCOSAHEXAENOIC ACID; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LINOLEIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 ACID ETHYL ESTER; OMEGA 3 FATTY ACID; PLACEBO; SIMVASTATIN;

ACUTE HEART INFARCTION; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIETARY INTAKE; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERUCTATION; EXERCISE; HEART VENTRICLE FIBRILLATION; HUMAN; HYPERTRIGLYCERIDEMIA; INFECTION; ISCHEMIC HEART DISEASE; MONOTHERAPY; MORTALITY; NONHUMAN; PATHOGENESIS; RASH; RESTENOSIS; REVIEW; RISK FACTOR; SIDE EFFECT; TACHYCARDIA; TASTE DISORDER; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VEIN GRAFT DISEASE;

EID: 45349107588     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Adult Treatment Panel III). Final report. Circulation 2002; 106:3143-3421. Available at: http://circ.ahajournals.org/cgi/content/full/106/25/3143.
2. Pownall HJ, Ballantyne CM, Kimball KT, et al. Effect of moderate alcohol consumption on hypertriglyceridemia: A study in the fasted state. Arch Intern Med 1999; 159:981-987.
3. Bang HO, Dyerberg J, Nielsen AB. Plasma lipids and lipoprotein pattern in Greenlandic West Coast Eskimos. Lancet 1971;1(7710):1143-1145.
4. Kris-Etherton PM, Harris WS, Appel LJ, for the Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747-2757.
5. Whelton SP, Whelton PK, Muntner P. Meta-analysis of observational studies on fish intake and coronary heart disease. Am J Cardiol 2004;93:1119-1123.
6. He K, Song Y, Daviglus ML, et al. Accumulated evidence on fish consumption and coronary heart disease mortality: A meta-analysis of cohort studies. Circulation 2004;109:2705-2711.
7. Structures and functions of omega-3 fatty acids. Available at http://en.wikipedia.org/wiki/%CE%91-linolenic_acid; http://en.wikipedia.org/ wiki/Eicosapentaenoic_acid; and http://en.wikipedia.org/wiki/ Docosahexaenoic_acid. Accessed July 6, 2007.
8. Omega-3. Available at: www.omacorrx.com. Accessed May 17, 2007.
9. Lovaza (Omacor) capsules, prescribing information. Liberty Corner, NJ: Reliant; 2005. Revised August 2007.
10. Bays H. Clinical overview of Omacor: A concentrated formulation of omega-3 polyunsaturated fatty acids. Am J Cardiol 2006;98(Suppl):71i-76i.
11. DHA for eyesight and mental acuity. Family Health News & Nutrition. Available at: www.familyhealthnews.com/articles_dha_for_eyesight.html. Accessed July 6, 2007.
12. Kris-Etherton PM, Harris WS, Appel LJ, for the AHA Nutrition Committee. Omega-3 fatty acids and cardiovascular disease: New recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol 2003;23:151-152.
13. Data on file. Liberty Corner, NJ: Reliant.
14. Bryhn M, Hansteen H, Schanche T, Aarke SE. The bioavailability and pharmacodynamics of different concentrations of omega-3 acid ethyl esters. Prostaglandins Leukot Essent Fatty Acids 2006; 75:19-24.
15. Mackness MI, Bhatnagar D, Durrington PN, et al. Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridemia. Eur J Clin Nutr 1994;48:859-865.
16. Lee KW, Lip GY. The role of omega-3 fatty acids in the secondary prevention of cardiovascular disease. Q J Med 2003;96: 465-480.
17. von Schacky C. A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels. Vasc Health Risk Manage 2006;2: 251-262.
18. Reiffel JA, McDonald A. Antiarrhythmic effects of omega-3 fatty acids. Am J Cardiol 2006;98(Suppl):50i-60i.
19. Duggal N, Tom WC. New drug: Omacor (omega-3 acid ethyl esters.) Pharmacist's Letter/Prescriber's Letter 2005;21. Detail Document No. 211003.
20. Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk 1997;4:385-391.
21. Pownall HJ, Brauchi D, Kilnic C, et al. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis 1999; 143:285-297.
22. Stalenhoef AF, de Graaf J, Wittekoek ME, et al. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low-density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia. Atherosclerosis 2000;153:129-138.
23. Van Dam M, Stalenhoef AFH, Wittekoek J, et al. Efficacy of concentrated omega-3 fatty acids in hypertriglyceridemia: A comparison with gemfibrozil. Clin Drug Invest 2001;21:175-181.
24. Durrington PN, Bhatnagar D, Mackness MI, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridemia. Heart 2001;85:544-548.
25. Nordoy A, Bonaa KH, Nilsen H, et al. Effects of simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidemia. J Intern Med 1998;243: 163-170.
26. Calabresi L, Donati D, Pazzucconi F, et al. Omacor in familial combined hyperlipidemia: Effects on lipids and low-density lipoprotein subclasses. Atherosclerosis 2000;148:387-396.
27. Eritsland J, Arnesen H, Berg K, et al. Serum Lp(a) lipoprotein levels in patients with coronary artery disease and the influence of long-term n-3 fatty acid supplementation. Scand J Clin Lab Invest 1995;55:295-300.
28. Grundt H, Nilsen DW, Hetland O, et al. Improvement of serum lipids and blood pressure during intervention with n-3 fatty acids was not associated with changes in insulin levels in subjects with combined hyperlipidemia. J Intern Med 1995; 237:249-259.
29. Lungerhausen YK, Abbey M, Nestel PJ, Howe PRC. Reduction of blood pressure and plasma triglycerides by omega-3 fatty acids in treated hypertensives. J Hypertens 1994;12:1041-1045.
30. Russo C, Olivieri O, Girelli D, et al. Omega-3 polyunsaturated fatty acid supplementation and ambulatory blood pressure monitoring parameters in patients with mild essential hypertension. J Hypertens 1995;13:1823-1826.
31. Chan DC, Watts GF, Barrett HR, et al. Effect of atorvastatin and fish oil on plasma high sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin Chem 2002;48: 877-963.
32. Nilson DWT, Albrelasen G, Landmark K, et al. Effects of a high-dose concentration of n-3 fatty acids or corn oil introduced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol. Am J Clin Nutr 2001;74:50-56.
33. Eritsland L, Arnesen H, Gronseth K, et al. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol 1996;77:31-36.
34. Johansen O, Brekke M, Seljeflot I, et al., Coronary Angioplasty Restenosis Trial. n-3 fatty acids do not prevent restenosis after coronary angioplasty: Results from the CART study. J Am Coll Cardiol 1999; 33:1619-1626.
35. The GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISS-Prevenzione trial. Lancet 1999;354: 447-455.
36. Bucher HC, Hengstler P, Schindler C, Meier G. n-3 polyunsaturated fatty acids in coronary heart disease: A meta-analysis of randomized controlled trials. Am J Med 2002;112:298-304.
37. Studer M, Briel M, Leimensoll B, et al. Effects of different antilipidemic agents and diets on mortality. Arch Intern Med 2005; 165:725-730.
38. Hooper L, Thompson RL, Harrison RA, et al. Omega-3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev 2006. Issue 2.
39. von Schacky C. Omega-3 fatty acids and cardiovascular disease. Curr Opin Clin Nutr Metab Care 2007;10:129-135.
40. McKenney JM, Swearingen D, Di Spirito M, et al. Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters. J Clin Pharmacol 2006;46:785-791.
41. McClaskey EM, Michalets EL. Subdural hematoma after a fall in an elderly patient taking high-dose omega-3 fatty acids with warfarin and aspirin: Case report and review of the literature. Pharmacotherapy 2007;27:152-160.
42. Onochie L. Personal communication, GlaxoSmithKline, April 23, 2008.
43. TriCor (fenofibrate) tablets, prescribing information. North Chicago, IL: Abbott; 2004.
44. Lopid (gemfibrozil) tablets, prescribing information. New York: Parke-Davis, Division of Pfizer, Inc.; 2003.
45. Niaspan (niacin) extended-release tablets, prescribing information. Cranbury, NJ: Kos; 2007.
46. Formulary dossier: Submission of clinical and economic data supporting formulary consideration of Omacor (omega-3 acid ethyl esters) capsules. Reliant; 2005.
47. Drugstore.com. Available at: www.drugstore.com. Accessed May 17, 2008.
48. Epocrates Rx Pro. Available at: www.epocrates.com. Accessed April 14, 2008.